pharmaphorum

OCTOBER 28, 2020

Data defines modern therapeutics, but this is almost uniquely confined to the clinical trial stages of drug development. PE isn’t traditional ‘communications’ where organisations talk to try and change patient behaviours, rather it’s about listening to patients to change corporate behaviours.

Vaccines 118

Vaccines Hospitals Pharmaceutical Companies Pharmaceutical Companies 118

pharmaphorum

APRIL 11, 2022

Medicines and vaccines are among the most powerful interventions that can help improve quality of life for people across the world. Delivering value for patients doesn’t start and end in our R&D labs; actions can be implemented across all stages of the drug development lifecycle to encourage and embrace a pro-innovation environment.

Pharmaceutical Companies 114

Pharmaceutical Companies Pharmaceutical Companies Vaccines Packaging 114

Pharmaceutical Technology

FEBRUARY 1, 2023

RSV researchers at major pharmaceutical companies are currently working to develop new RSV drugs to beat future waves of RSV infection and gain the first RSV vaccine FDA approval. Pharmaceutical companies are pushing to develop drugs and vaccines for RSV with these populations in mind.

Vaccines 64

Vaccines Drug Development Pharmaceutical Companies Pharmaceutical Companies 64

pharmaphorum

MAY 27, 2022

Teams and Zoom became the backbone of communication and firms embraced new ways of working. However, if considered early in the drug development plan, compliance is by no means insurmountable and would be offset by the benefits of digital healthcare tools for patient engagement.

Packaging 79

Packaging Generic Medicine Communication Hospitals 79

pharmaphorum

SEPTEMBER 9, 2021

Public health agencies and pharma pivoted in countless ways, from decentralising clinical trials and accelerating research and development, to enabling remote care and remote working with rapid digitisation. And we transformed so quickly because the key players communicated and collaborated.

Communication 52

Communication Pharmaceutical Companies Pharmaceutical Companies Hospitals 52

pharmaphorum

MARCH 30, 2021

“There’s a lot that drug development for more common diseases could learn from rare disease R&D”. I think there’s a lot that drug development for more common diseases could learn from rare disease R&D.”. We have to be innovative to get around those challenges. Rare diseases during COVID.

Hospitals 110

Hospitals Communication Drug Development Pharmaceutical Companies 110

PharmaShots

APRIL 3, 2023

of the newly combined company The combined companies’ focus is to advance Elicio’s lymph node-targeting amphiphile technology to develop immunotherapies & also focus on ELI-002, a therapeutic cancer vaccine targeting mKRAS-driven tumors is currently being evaluated in the P-I trial (AMPLIFY-201) for PDAC and CRC.

Biosimilars 40

Biosimilars Diabetes Compounding Hospitals 40

Pharmaceutical Technology

MARCH 24, 2023

Since the first human administration of the Bacillus Calmette-Guérin vaccine in 1921, no one has been able to successfully follow the vaccine’s path to become the next approved vaccine to tackle tuberculosis (TB). However, as the TB-related death toll remains high, the global need for another vaccine is steadily rising.

Vaccines 64

Vaccines Health and Personal Care Stores Immunity Immunization 64

Pharmaceutical Technology

APRIL 24, 2023

Since then, the field of nanomedicine has steadily progressed to reach high points such as the successful use of nanotechnology to deliver messenger RNA (mRNA)-based Covid-19 vaccines. In the case of most mRNA vaccines, a lipid nanoparticle-based approach was chosen due to its ability to protect the mRNA in the body and prevent degradation.

Vaccines 59

Vaccines Immunity Immunization Medical Schools 59

Pharmaceutical Technology

APRIL 12, 2023

The Association of the British Pharmaceutical Industry (ABPI) also states that “the use of animals in medical research has played and continues to play an essential role in the development of new medicines and vaccines”. The topic of animal testing remains a fiercely contentious topic in the public eye.

Vaccines 98

Vaccines Biosimilars Communication Pharmaceutical Companies 98

Pharmaceutical Technology

FEBRUARY 20, 2023

We are delighted to deepen our partnership with Teddy Lab that will enable us to build on existing knowledge and increase services within China to support customers with their global drug development programmes. Teddy Lab has been a trusted partner for many years and mirrors our commitment to high-quality, patient-centric solutions.

Research Laboratories 52

Research Laboratories Drug Development Vaccines Communication 52

Pharmaceutical Technology

DECEMBER 8, 2022

Instead of starting with ‘what equipment do we have’, we’re really starting with our end goal by considering what is required by the drug developers,” explains Lenaerts. This is something that sets Datwyler’s approach apart from its competitors. Lessons from the Pandemic: Building a Better Prefilled Syringe. By Datwyler. United States.

Packaging 98

Packaging Vaccines Communication Drug Development 98

Pharmaceutical Technology

MARCH 22, 2023

Several drug development trends are driving injectables demand. This includes the rising number of biologic drugs on the market, which are mostly administered parenterally. During the Covid-19 pandemic, large-scale vaccine production placed unprecedented demand on the parenteral packaging industry.

Packaging 52

Packaging Compounding Pharmaceutical Companies Pharmaceutical Companies 52

Pharmaceutical Technology

FEBRUARY 20, 2023

On the other hand, a lack of diversity in clinical trial populations, particularly when the disease population is significantly underrepresented, greatly diminishes the quality of data obtained for drug safety and efficacy profiles. This may sound obvious, but it is still a major hurdle in drug development.

Vaccines 52

Vaccines Communication Immunity Immunization 52

Pharmaceutical Technology

APRIL 27, 2023

The successful development and deployment of the mRNA-based COVID-19 vaccines has catalysed the biopharma industry and paved the way to expand this drug modality to new therapeutic areas. Excluding vaccines, there are five mRNA therapeutic products in clinical trial development as of November 2022.

Vaccines 52

Vaccines Drug Development Documentation Communication 52